Mammoth Biosciences has developed a detection platform based on CRISPR technology, aimed at making disease detection accessible to all. Their platform offers an efficient and cost-effective point-of-need test which can quickly detect multiple conditions simultaneously. This enables healthcare providers, researchers, and biotech professionals to leverage this innovative platform for molecular diagnostics.

Investors Include:

University of California, Decheng Capital, Tachyon Ventures, Tectonic Capital, Foresite Capital Management, K50 Ventures, Berkeley Frontier Fund, Plum Alley Investments, Boom Capital Ventures, Sixth Street Partners, Wireframe Ventures, Redmile Group, DHVC, Amazon.com, Mission Bay Capital, Berkeley, 8VC, Kairos HQ, Mission BioCapital, Brook Byers, Plug and Play Tech Center, Verily Life Sciences, Senator Investment Group, NFX, Vectr Ventures.

Looking to sell Mammoth Biosciences Stock or Options?

We have an even better solution: The Collective Exchange Fund

Get in touch and see if we can help you